Septerna, Inc. announced SEP-204 as its lead candidate for treating Graves' disease and thyroid eye disease (TED). SEP-204 is an oral drug that inhibits the thyroid-stimulating hormone receptor (TSHR), showing promising preclinical results including normalization of thyroid hormone levels and reduction of symptoms in animal models. The drug is expected to support once-daily dosing and is set to enter Phase 1 clinical trials in healthy volunteers in early 2027. This development could offer a new treatment option addressing the root cause of these autoimmune diseases, which current therapies do not fully target.
Septerna's announcement of SEP-204 as a development candidate for Graves' disease and thyroid eye disease provides context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 18:41 WIB: out of 150 priced US health-sector stocks, 118 rose and 24 fell. Notable movers include OSCR (Oscar Health Inc) at USD 34.95 with a 7.84% increase and Pluang order activity showing 16% Sell / 84% Buy, RVTY (Revvity Inc) at USD 173.82 up 6.32% with 0% Sell / 100% Buy, and NUVB (Nuvation Bio Inc. Class A) at USD 4.98 up 6.18%.
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced its participation in several investor conferences in November and December 2026, including events hosted by Stifel, Truist Securities, UBS, ...
etoro has agreed to acquire LB Finanzas, a leading Argentine all-in-one financial app, to strengthen its presence in Latin America's fast-growing fintech market. LB Finanzas offers integrated investing and payment solutions, catering to Argentine ret...
JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...
KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...
Dimensional Fund Advisors Ltd. filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc as of November 3, 2026. This disclosure is part of regulatory requirements under the Takeover Code for investors holding 1% or more in relevan...
